Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 559 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Acupressure for Fatigue in Systemic Lupus Erythematosus

NCT03200548
Conditions
Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life, Sleep
Interventions
Relaxing acupressure plus usual care, Usual care, Stimulating acupressure plus usual care, Sham acupressure plus usual care
Behavioral
Lead sponsor
Suzanna Zick
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus
Interventions
Belimumab, Belimumab/Placebo, Placebo
Biological · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Systemic Lupus Erythematosus
Interventions
P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine, Rimiducid
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
Birmingham, Alabama • Iowa City, Iowa
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Glomerulonephritis, Membranoproliferative, Lupus Nephritis
Interventions
BG9588
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions
ADI-001, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Redwood City, California • Buffalo, New York
Conditions
Inflammation, Systemic Lupus Erythematosus
Interventions
NNC 0151-0000-0000, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lake Success, New York
Conditions
Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury
Interventions
Dexamethasone or other corticosteroid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
4
States / cities
New Haven, Connecticut • Livingston, New Jersey • New York, New York
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
3
States / cities
Birmingham, Alabama • Galveston, Texas • Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Genetic Study of Lupus Patients and Their Families

NCT00235378
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
2,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Systemic Lupus Erythematosus
Interventions
Levothyroxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Systemic Lupus Erythematosus
Interventions
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
Interventions
Not listed
Lead sponsor
Lupus Foundation of America
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
System; Lupus Erythematosus
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years · Female only
U.S. locations
1
States / cities
Sugar Land, Texas
Completed No phase listed Observational Accepts healthy volunteers

Functional MRI in Lupus Nephritis

NCT01731054
Conditions
Healthy, Lupus Nephritis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Los Angelos, California • Torrance, California • The Bronx, New York + 1 more
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Conditions
System; Lupus Erythematosus
Interventions
Mymee Program
Behavioral
Lead sponsor
Mymee Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Lupus Nephritis
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Glendale, Arizona • La Palma, California • Los Angeles, California + 13 more
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
rapcabtagene autoleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
17
States / cities
Birmingham, Alabama • San Bernardino, California • San Francisco, California + 11 more
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Interventions
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
Biological
Lead sponsor
iCell Gene Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Hawthorne, New York • New Hyde Park, New York + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of AMG 570 in Healthy Subjects

NCT02618967
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 570, AMG 570 Matching Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin
Conditions
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions
LY2127399, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Irving, Texas